TIL

MKT CAP:$54M

Instil Bio, Inc.

Market Cap

$54M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.18-$3.09 (-27.42%)

Apr 23, 2026

Company Details

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in p...

CEO

Bronson Crouch

IPO Date

Mar 19, 2021

Website

instilbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$71M

EPS (Diluted)

-$10.78

Free Cash Flow

-$37M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 27, 2026

$0EPS -$10.70

Q4 2025

Mar 27, 2026

$0EPS -$1.21

Q3 2025

Nov 13, 2025

$0EPS -$2.01

Q2 2025

Aug 13, 2025

$0EPS -$3.24

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$54M
Q2 22	$0	$0	-$59M
Q3 22	$0	$0	-$57M
Q4 22	$0	$0	-$57M
Q1 23	$0	$0	-$58M
Q2 23	$0	$0	-$21M
Q3 23	$0	$0	-$67M
Q4 23	$0	-$1M	-$13M
Q1 24	$0	-$993.0K	-$20M
Q2 24	$0	$0	-$14M
Q3 24	$0	$0	-$24M
Q4 24	$0	-$741.0K	-$11M
Q1 25	$0	$0	-$31M
Q2 25	$0	$0	-$23M
Q3 25	$0	-$12.0K	-$15M
Q4 25	$0	-$12.0K	-$10M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$55M	-$75M
Q2 22	-$47M	-$73M
Q3 22	-$41M	-$66M
Q4 22	-$37M	-$50M
Q1 23	-$35M	-$43M
Q2 23	-$20M	-$27M
Q3 23	-$14M	-$20M
Q4 23	-$13M	-$13M
Q1 24	-$14M	-$14M
Q2 24	-$11M	-$11M
Q3 24	-$20M	-$20M
Q4 24	-$11M	-$11M
Q1 25	-$4M	-$4M
Q2 25	-$15M	-$15M
Q3 25	-$11M	-$11M
Q4 25	-$7M	-$7M

Capital Expenditures

Quarter	CapEx
Q1 22	$20M
Q2 22	$26M
Q3 22	$25M
Q4 22	$13M
Q1 23	$8M
Q2 23	$7M
Q3 23	$5M
Q4 23	$58.0K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+132.0%
Q2 22	—	+66.0%
Q3 22	—	+31.7%
Q4 22	—	+5.7%
Q1 23	—	+7.7%
Q2 23	—	-64.3%
Q3 23	—	+17.8%
Q4 23	—	-77.4%
Q1 24	—	-66.3%
Q2 24	—	-32.6%
Q3 24	—	-64.6%
Q4 24	—	-10.8%
Q1 25	—	+55.3%
Q2 25	—	+65.8%
Q3 25	—	-36.4%
Q4 25	—	-16.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$5M	—
Q2 23	$4M	—
Q3 23	$5M	—
Q4 23	$5M	—
Q1 24	$5M	—
Q2 24	$4M	—
Q3 24	$4M	—
Q4 24	$5M	—
Q1 25	$3M	—
Q2 25	$2M	—
Q3 25	$2M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$39M	$15M	—
Q2 22	$42M	$17M	—
Q3 22	$40M	$17M	—
Q4 22	$21M	$13M	—
Q1 23	$21M	$13M	—
Q2 23	$8M	$12M	—
Q3 23	$8M	$12M	—
Q4 23	$2M	—	$10M
Q1 24	$7M	$12M	—
Q2 24	$3M	$11M	—
Q3 24	$562.0K	$11M	—
Q4 24	$1M	—	$10M
Q1 25	$5M	$9M	—
Q2 25	$7M	$6M	—
Q3 25	$9M	$6M	—
Q4 25	$3M	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$61M	$318M	$380M
Q2 22	$42M	$312M	$355M
Q3 22	$41M	$262M	$303M
Q4 22	$44M	$217M	$261M
Q1 23	$27M	$196M	$223M
Q2 23	$22M	$180M	$202M
Q3 23	$9M	$174M	$183M
Q4 23	$9M	$141M	$150M
Q1 24	$5M	$148M	$154M
Q2 24	$7M	$142M	$149M
Q3 24	$7M	$114M	$120M
Q4 24	$9M	$105M	$113M
Q1 25	$15M	$88M	$104M
Q2 25	$8M	$84M	$92M
Q3 25	$6M	$74M	$80M
Q4 25	$7M	$69M	$76M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	129M	+0.1%	+269.2%
Q2 22	129M	+0.2%	+0.5%
Q3 22	130M	+0.2%	+0.7%
Q4 22	6M	-95.0%	-95.0%
Q1 23	7M	+0.2%	-95.0%
Q2 23	7M	0.0%	-95.0%
Q3 23	7M	0.0%	-95.0%
Q4 23	7M	-0.0%	+0.2%
Q1 24	7M	0.0%	-0.0%
Q2 24	7M	0.0%	-0.0%
Q3 24	7M	+0.0%	+0.0%
Q4 24	7M	+0.3%	+0.3%
Q1 25	7M	+0.1%	+0.4%
Q2 25	7M	+1.0%	+1.4%
Q3 25	7M	+2.4%	+3.9%
Q4 25	7M	+0.4%	+3.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	412
Q2 22	$0	412
Q3 22	$0	412
Q4 22	$0	192
Q1 23	$0	192
Q2 23	$0	192
Q3 23	$0	192
Q4 23	$0	49
Q1 24	$0	49
Q2 24	$0	49
Q3 24	$0	49
Q4 24	$0	14
Q1 25	$0	14
Q2 25	$0	14
Q3 25	$0	14
Q4 25	$0	200K

Revenue / Employee